Evidence map›Paper›PMID 42174637›Full record

ArticleJournal of nanobiotechnology2026

Ultrasound-responsive biomimetic nanocarrier triggers spatiotemporal PROTAC release and ROS storm to disrupt TNBC immunosuppression via coordinated apoptosis/ferroptosis/senescence activation.

Zhipeng Liao, Haiqin Liao, Yi Luo, Sihan Chen, Yuanyuan Shen, Ming Zhang, Yan Xu, Long Wang, Chengcheng Niu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhipeng LiaoDepartment of Ultrasound, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Haiqin LiaoDepartment of Ultrasound, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Yi LuoDepartment of Ultrasound, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Sihan ChenDepartment of Ultrasound, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Yuanyuan ShenDepartment of Ultrasound, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Ming ZhangDepartment of Ultrasound, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Yan XuDepartment of Ultrasound, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Long WangDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Chengcheng NiuDepartment of Ultrasound, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. niuchengcheng@csu.edu.cn.

Funding

Hunan Provincial Natural Science Foundation of China 2023JJ30804National Natural Science Foundation of China 82572252
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) poses significant therapeutic challenges due to its aggressive metastasis and immunosuppressive microenvironment. Herein, we developed a tumor-targeting biomimetic nanosystem (MTB@LM) integrating BRD4-targeting PROTAC (dBET6), Mn-TCPP-based sonosensitizers, and a tumor cell membrane-fusogenic liposome hybrid membrane coating. MTB@LM efficiently accumulates in tumors via homologous targeting and bypasses lysosomal degradation through membrane fusion-mediated delivery. Under ultrasound activation, the nanosystem triggers a multimodal cascade: (1) Mn-enhanced sonodynamic therapy (SDT) amplifies ROS to overcome hypoxia/GSH resistance; (2) BRD4 degradation synergizes with SDT to induce apoptosis, while concurrent ferroptosis (via lipid peroxidation) and senescence (via p21/p16 activation) amplify immunogenic cell death (ICD); (3) Senescent tumor cells are eliminated by αPD-L1 to block immune evasion. In orthotopic 4T1 models, MTB@LM + US achieved > 85% tumor suppression and remodeled the immunosuppressive microenvironment by promoting dendritic cell maturation, CD8⁺ T cell infiltration, and M1 macrophage repolarization. Combining MTB@LM with αPD-L1 synergistically inhibited lung metastasis (> 90%) and established durable immune memory against recurrence. This nanotechnology-driven strategy integrates PROTAC delivery, SDT-amplified ICD, and senolytic immunotherapy, offering a promising paradigm for combating metastatic TNBC.

Indexed as

Biomimetic MaterialsNanoparticlesReactive Oxygen SpeciesTriple Negative Breast NeoplasmsAnimalsApoptosisBiomimeticsBromodomain Containing ProteinsCell Line, TumorCellular SenescenceFemaleHumansLiposomesMiceMice, Inbred BALB CProteolysis Targeting ChimeraBromodomain Containing ProteinsLiposomesProteolysis Targeting ChimeraReactive Oxygen SpeciesTranscription FactorsBiomimetic nanoparticlesBRD4-targeting PROTACFerroptosisImmunogenic cell deathSenescenceSonodynamic therapyαPD-L1 immunotherapy

Identifiers

PMID42174637
PMCPMC13383570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.